Jacobs Levy Equity Management
VIR icon

Jacobs Levy Equity Management’s Vir Biotechnology VIR Stock Holding History

Jacobs Levy Equity Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9M Buy
+1,442,336
New +$11.5M 0.05% 273
2025
Q4 		– Sell
-96,717
Closed -$552K – 1068
2025
Q3 		$552K Sell
96,717
-48,581
-33% -$248K ﹤0.01% 805
2025
Q2 		$732K Buy
145,298
+89,846
+162% +$482K ﹤0.01% 816
2025
Q1 		$359K Buy
+55,452
New +$493K ﹤0.01% 959
2024
Q4 		– Sell
-350,265
Closed -$2.62M – 1050
2024
Q3 		$2.62M Buy
350,265
+33,473
+11% +$291K 0.01% 551
2024
Q2 		$2.82M Buy
316,792
+6,701
+2% +$64.3K 0.01% 545
2024
Q1 		$3.14M Buy
310,091
+16,615
+6% +$169K 0.01% 516
2023
Q4 		$2.95M Buy
293,476
+12,876
+5% +$118K 0.01% 536
2023
Q3 		$2.63M Buy
+280,600
New +$4M 0.02% 518
2022
Q4 		– Sell
-19,169
Closed -$370K – 1045
2022
Q3 		$370K Buy
+19,169
New +$487K ﹤0.01% 870

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Jacobs Levy Equity Management's VIR Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in Vir Biotechnology (VIR) in Q1 2026: 1,442,336 shares worth $12.9M. The stake represents 0.05% of the portfolio and ranks #273 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in VIR as recently as Q3 2025.

Jacobs Levy Equity Management first reported a position in VIR in Q3 2022 and has held it in 10 quarters since. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Jacobs Levy Equity Management held 1,442,336 shares of Vir Biotechnology worth $12.9M as of Q1 2026.
  • Vir Biotechnology was a new Jacobs Levy Equity Management position in Q1 2026.
  • Vir Biotechnology made up 0.05% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #273 holding.
  • Jacobs Levy Equity Management first reported a position in Vir Biotechnology in Q3 2022 and has held it in 10 quarters since.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.